GlassScriptPhysician profile
Don A Gibson
NPI 1881797439
$1,558.41
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $35.73 · 2021: $44.12 · 2022: $17.94 · 2023: $139 · 2024: $32.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $169.27 | 2019-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $145.07 | 2019 | |
| Avanir Pharmaceuticals, INC. | $139.97 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.50 | 2019 | |
| Pfizer INC. | $117.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $113.64 | 2019-2020 | |
| Mylan Specialty L.P. | $112.88 | 2019 | |
| Merck Sharp & Dohme LLC | $93.73 | 2023 | Verquvo |
| Mdd US Operations, LLC | $88.36 | 2019 | |
| Amgen INC. | $69.29 | 2019 | |
| Sunovion Pharmaceuticals INC. | $67.19 | 2019 | |
| Abbott Laboratories | $63.93 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Emmaus Medical, INC. | $49.60 | 2020-2021 | |
| Indivior INC. | $47.12 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $19.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.